Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Dobrowolska, Justyna A ^a   Kasten, Tom ^a   Huang, Yafei ^a   Benzinger, Tammie L S ^b   Sigurdson, Wendy ^a   Ovod, Vitaliy ^a   Morris, John C ^a   Bateman, Randall J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID PRECURSOR PROTEIN ALPHA; UNCLASSIFIED DRUG; ALPHA-SAPP PROTEIN, HUMAN; AMYLOID BETA-PROTEIN (10-40); AMYLOID BETA-PROTEIN (40-42); PEPTIDE FRAGMENT;

ADULT; AGING; ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METABOLITE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS; REGULATORY MECHANISM; AGED; CASE CONTROL STUDY; CEREBROSPINAL FLUID; METABOLISM; MIDDLE AGED; PATHOLOGY; VASCULAR AMYLOIDOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM; CEREBRAL AMYLOID ANGIOPATHY; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84898612024     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089998     Document Type: Article

References (37)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112-2117. (Pubitemid 41797645)
2. De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde G, et al. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391:387-390. (Pubitemid 28093512)
3. Galasko D, Chang L, Motter R, Clark CM, Kaye J, et al. (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55:937-945. (Pubitemid 28335112)
4. (1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 56:673-680.
5. 42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults. Arch Neurol 64:343-349.
6. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's Disease: the challenge of the second century. Sci Transl Med 3:77sr1.
7. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68:666-669. (Pubitemid 46667813)
8. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, et al. (2009) Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science 326:1005-1007.
9. Huang Y, Potter R, Sigurdson W, Santacruz A, Shih S, et al. (2012) Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system. Arch Neurol 69:51-58.
10. Huang Y, Potter R, Sigurdson W, Kasten T, Connors R, et al. (2012) β-amyloid dynamics in human plasma. Arch Neurol 69:1591-1597.
11. Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener 6:27.
12. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, et al. (1999) Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735-741.
13. Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, et al. (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402:533-537.
14. Lin X, Koelsch G, Wu S, Downs D, Dashti A, et al. (2000) Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 97:1456-1460. (Pubitemid 30118462)
15. 11C] PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67:446-452.
16. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55:306-319. (Pubitemid 38269583)
17. Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, et al. (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol 59:512-519. (Pubitemid 43358072)
18. Bateman RJ, Wen G, Morris JC, Holtzman DM (2007) Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 68:666-669. (Pubitemid 46667813)
19. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, et al (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
20. Kim KS, Miller DL, Sapienza VJ, Chen C-MJ, Bai C, et al. (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2:121-130.
21. Roh JH, Huang Y, Bero AW, Kasten T, Stewart FR, et al. (2012) Disruption of the sleep-wake cycle and diurnal fluctuation of β-amyloid in mice with Alzheimer's disease pathology. Sci Transl Med 4:150ra122.
22. Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP, et al. (2011) Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 306:613-619.
23. Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, et al. (2011) Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol 70:722-732.
24. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, et al. (2013) Sleep drives metabolite clearance from the adult brain. Science 342:373-377. doi: 10.1126/science.1241224.
25. Haimov I, Lavie P (1997) Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Sleep 20:294-300. (Pubitemid 27276645)
26. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, et al. (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15:138-145.
27. Gabelle A, Roche S, Gény C, Bennys K, Labauge P, et al. (2010) Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res 1357:175-183.
28. Alexopoulos P, Tsolakidou A, Roselli F, Arnold A, Grimmer T, et al. (2012) Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement 8:304-311.
29. Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, et al. (2013) Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Res 1513:117-126.
30. Gandy SE, Buxbaum JD, Suzuki T, Ramabhadran TV, Caporaso GL, et al. (1992) The nature and metabolism of potentially amyloidogenic carboxylterminal fragments of the Alzheimer beta/A4-amyloid precursor protein: some technical notes. Neurobiol Aging 13:601-603.
31. Buxbaum JD, Koo EH, Greengard P (1993) Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. Proc Natl Acad Sci U S A 90:9195-9198. (Pubitemid 23306479)
32. Savage MJ, Trusko SP, Howland DS, Pinsker LR, Mistretta S, et al. (1998) Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J Neurosci 18:1743-1752. (Pubitemid 28103082)
33. Skovronsky DM, Moore DB, Milla ME, Doms RW, Lee VM-Y (2000) Protein Kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the Trans-Golgi Network. J Biol Chem 275:2568-2575. (Pubitemid 30082022)
34. Kim M, Suh J, Romano D, Truong MH, Mullin K, et al. (2009) Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity. Hum Mol Genet 18:3987-3996.
35. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, et al. (2011) Robust central reduction of Amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor. J Neurosci 31:16507-16516.
36. Sankaranarayanan S, Price EA, Wu G, Crouthamel MC, Shi XP, et al. (2008) In vivo β-secretase 1 inhibition leads to brain Aβ lowering and increased α-secretase processing of amyloid precursor protein without effect on neuregulin-1. J Pharmacol Exp Ther 324:957-969. (Pubitemid 351397853)
37. Olsson A, Höglund K, Sjögren M, Andreasen N, Minthon L, et al. (2003) Measurement of α- and β-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp Neurol 183:74-80. (Pubitemid 37075858)